IL162118A0 - Pharmaceutical compositions containing an orally active taxane derivative - Google Patents

Pharmaceutical compositions containing an orally active taxane derivative

Info

Publication number
IL162118A0
IL162118A0 IL16211802A IL16211802A IL162118A0 IL 162118 A0 IL162118 A0 IL 162118A0 IL 16211802 A IL16211802 A IL 16211802A IL 16211802 A IL16211802 A IL 16211802A IL 162118 A0 IL162118 A0 IL 162118A0
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
compositions containing
orally active
taxane derivative
active taxane
Prior art date
Application number
IL16211802A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IL162118A0 publication Critical patent/IL162118A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL16211802A 2001-12-20 2002-12-12 Pharmaceutical compositions containing an orally active taxane derivative IL162118A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34288901P 2001-12-20 2001-12-20
PCT/US2002/040127 WO2003053350A2 (en) 2001-12-20 2002-12-12 Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability

Publications (1)

Publication Number Publication Date
IL162118A0 true IL162118A0 (en) 2005-11-20

Family

ID=23343716

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16211802A IL162118A0 (en) 2001-12-20 2002-12-12 Pharmaceutical compositions containing an orally active taxane derivative

Country Status (24)

Country Link
US (1) US20030220391A1 (xx)
EP (1) EP1465618A2 (xx)
JP (1) JP2006501134A (xx)
KR (1) KR20040066921A (xx)
CN (1) CN1273130C (xx)
AR (1) AR037951A1 (xx)
AU (1) AU2002361701A1 (xx)
BR (1) BR0215184A (xx)
CA (1) CA2470826A1 (xx)
GE (1) GEP20063806B (xx)
HR (1) HRP20040545A2 (xx)
HU (1) HUP0500843A2 (xx)
IL (1) IL162118A0 (xx)
IS (1) IS7306A (xx)
MX (1) MXPA04005877A (xx)
NO (1) NO20043101L (xx)
PE (1) PE20030742A1 (xx)
PL (1) PL374283A1 (xx)
RS (1) RS52904A (xx)
RU (1) RU2004119557A (xx)
TW (1) TW200302086A (xx)
UY (1) UY27598A1 (xx)
WO (1) WO2003053350A2 (xx)
ZA (1) ZA200404584B (xx)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003215885B2 (en) * 2002-02-25 2008-07-03 Lyfjathroun Hf Absorption enhancing agent
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
KR100533458B1 (ko) 2002-07-20 2005-12-07 대화제약 주식회사 파클리탁셀의 가용화용 조성물 및 그의 제조 방법
EP1498120A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Semi-solid formulations for the oral administration of taxoids
AU2004275881A1 (en) 2003-09-25 2005-04-07 Tapestry Pharmaceuticals, Inc. 9,10-alpha,alpha-OH-taxane analogs and methods for production thereof
US20060088591A1 (en) * 2004-10-22 2006-04-27 Jinghua Yuan Tablets from a poorly compressible substance
US20060116420A1 (en) * 2004-11-23 2006-06-01 Ramakrishnan Chidambaram Crystalline forms of 3'-tert-Butyl-3'-N-tert-butyloxycarbonyl-4-deacetyl-3'-dephenyl-3'-N-debenzoyl-4-O-methoxycarbonyl-paclitaxel
AU2012202903B2 (en) * 2005-02-18 2014-12-11 Abraxis Bioscience, Inc. Drugs with improved hydrophobicity for incorporation in medical devices
JP5139814B2 (ja) * 2005-02-18 2013-02-06 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー 医療装置に結合した改善された疎水性を有した薬剤
EP2433653B1 (en) 2005-07-15 2019-06-05 Angiochem Inc. Use of aprotinin polypeptides as carriers in pharmaceutical conjugates
US20070015834A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing PEG/Poloxamer
PL3311805T3 (pl) 2005-08-31 2020-07-27 Abraxis Bioscience, Llc Kompozycje zawierające słabo rozpuszczalne w wodzie środki farmaceutyczne i środki przeciwdrobnoustrojowe
WO2007134354A1 (de) * 2006-05-23 2007-11-29 Ebewe Pharma Ges.M.B.H. Nfg. Kg Pharmazeutische formulierung
US11786504B2 (en) 2006-09-28 2023-10-17 Tapestry Pharmaceuticals, Inc. Taxane analogs for the treatment of brain cancer
WO2008106621A1 (en) * 2007-02-28 2008-09-04 Tapestry Pharmaceuticals, Inc Taxane analogs for the treatment of brain cancer
WO2008121476A1 (en) 2007-03-28 2008-10-09 Tapestry Pharmaceuticals, Inc. Biologically active taxane analogs and methods of treatment by oral administration
US11873308B2 (en) 2006-11-06 2024-01-16 Tapestry Pharmaceuticals, Inc. Biologically active taxane analogs and methods of treatment by oral administration
EP1946747A1 (en) * 2007-01-17 2008-07-23 Sandoz AG Pharmaceutical composition of improved stability containing taxane derivatives
US9089544B2 (en) * 2007-08-24 2015-07-28 Slotervaart Participaties Bv Composition
KR101544498B1 (ko) * 2007-08-24 2015-08-17 스티칭 허트 네덜란드 칸커 인스티튜트 종양성 질환의 치료를 위한 조성물
US20100267787A1 (en) * 2007-11-12 2010-10-21 Gregory Harasymiw Pharmaceutical Compositions
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
ES2344674B1 (es) 2008-08-07 2011-06-29 Gp Pharm, S.A. Composicion farmaceutica inyectable de taxanos.
WO2010043047A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
EP2414560B1 (de) 2009-03-31 2013-10-23 Boehringer Ingelheim International GmbH Verfahren zur beschichtung einer oberfläche eines bauteils
JP5763053B2 (ja) 2009-05-18 2015-08-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アダプタ、吸入器具及びアトマイザ
CN102038635A (zh) 2009-10-23 2011-05-04 天津天士力集团有限公司 一种含有pH值调节剂的紫杉烷类药物溶液及其制备方法
WO2011064164A1 (en) 2009-11-25 2011-06-03 Boehringer Ingelheim International Gmbh Nebulizer
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
JP5658268B2 (ja) 2009-11-25 2015-01-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
WO2011160932A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Nebulizer
WO2012130757A1 (de) 2011-04-01 2012-10-04 Boehringer Ingelheim International Gmbh Medizinisches gerät mit behälter
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
WO2013152894A1 (de) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Zerstäuber mit kodiermitteln
EP2777691A1 (en) * 2013-03-14 2014-09-17 Pharmachemie B.V. Taxoid - Purification of Liquid Excipients
JP6643231B2 (ja) 2013-08-09 2020-02-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
EP2835146B1 (en) 2013-08-09 2020-09-30 Boehringer Ingelheim International GmbH Nebulizer
PL3139984T3 (pl) 2014-05-07 2021-11-08 Boehringer Ingelheim International Gmbh Nebulizator
LT3928818T (lt) 2014-05-07 2023-03-27 Boehringer Ingelheim International Gmbh Purkštuvas ir talpa
JP6580070B2 (ja) 2014-05-07 2019-09-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 容器、ネブライザ、及び使用
CN103980232A (zh) * 2014-06-05 2014-08-13 北京诺普德医药科技有限公司 10-乙酰基多西紫杉醇及其用途
DK3307326T3 (da) 2015-06-15 2020-10-19 Angiochem Inc Fremgangsmåder til behandling af leptomeningeal karcinomatose
TWI838700B (zh) * 2015-09-30 2024-04-11 香港商慧源香港創新有限公司 口服紫杉烷組合物及方法
CN108066335B (zh) * 2016-11-11 2020-02-21 北京康辰药业股份有限公司 一种含有紫杉醇或其类似物的药物组合物及其制备方法
FR3113238B1 (fr) 2020-08-05 2024-04-05 Gattefosse Sas Utilisation comme excipient, d’un melange de macrogolglyceride laurique et de polyethylene glycol

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5817321A (en) * 1992-10-08 1998-10-06 Supratek Pharma, Inc. Biological agent compositions
CA2149150C (en) * 1992-11-27 2000-08-01 David R. Carver Injectable taxol composition with improved stability
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6395770B1 (en) * 1995-10-26 2002-05-28 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
SI0932399T1 (sl) * 1996-03-12 2006-10-31 Pg Txl Co Lp Vodotopna paklitakselna predzdravila
CA2189916C (en) * 1996-11-08 2001-01-16 Parkash S. Gill A new regime for paclitaxel in kaposi's sarcoma patients
US6515016B2 (en) * 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US5980936A (en) * 1997-08-07 1999-11-09 Alliance Pharmaceutical Corp. Multiple emulsions comprising a hydrophobic continuous phase
HUP0101457A3 (en) * 1997-12-31 2003-01-28 Bristol Myers Squibb Co Antitumor 2-aroyl-4-acyl paclitaxel analogs and medicaments containing them , their intermediates and method for producing them
IL131217A0 (en) * 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
US6979456B1 (en) * 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
JP2002544269A (ja) * 1999-05-17 2002-12-24 ブリストル−マイヤーズ スクイブ カンパニー パクリタキセルおよびパクリタキセル類似体の製造におけるシリルエーテルの切断のための新規反応条件
HUP0202448A3 (en) * 1999-08-11 2005-02-28 Bristol Myers Squibb Co Process for preparation of paclitaxel c-4 methyl carbonate analog
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
US6916942B2 (en) * 2000-02-03 2005-07-12 Bristol-Myers Squibb Company Process for the preparation of C-4 carbonate taxanes
US6750246B1 (en) * 2000-02-03 2004-06-15 Bristol-Myers Squibb Company C-4 carbonate taxanes
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
JP2004536026A (ja) * 2000-11-28 2004-12-02 トランスフォーム ファーマシューティカルズ,インコーポレーティッド. パクリタキセル、その誘導体、および薬剤として許容される塩を含む医薬品製剤
TWI297335B (en) * 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
AU2002357012A1 (en) * 2001-11-27 2003-06-10 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof

Also Published As

Publication number Publication date
TW200302086A (en) 2003-08-01
GEP20063806B (en) 2006-04-25
AU2002361701A1 (en) 2003-07-09
ZA200404584B (en) 2005-09-13
HUP0500843A2 (hu) 2005-12-28
AR037951A1 (es) 2004-12-22
RU2004119557A (ru) 2005-04-20
BR0215184A (pt) 2006-06-06
HRP20040545A2 (en) 2005-08-31
CN1273130C (zh) 2006-09-06
NO20043101L (no) 2004-07-19
CN1606437A (zh) 2005-04-13
PL374283A1 (en) 2005-10-03
MXPA04005877A (es) 2004-09-13
IS7306A (is) 2004-06-10
WO2003053350A2 (en) 2003-07-03
WO2003053350A3 (en) 2004-01-15
PE20030742A1 (es) 2003-09-02
US20030220391A1 (en) 2003-11-27
EP1465618A2 (en) 2004-10-13
KR20040066921A (ko) 2004-07-27
RS52904A (xx) 2006-12-15
JP2006501134A (ja) 2006-01-12
UY27598A1 (es) 2003-07-31
CA2470826A1 (en) 2003-07-03

Similar Documents

Publication Publication Date Title
IL162118A0 (en) Pharmaceutical compositions containing an orally active taxane derivative
HUP0501186A2 (en) Pharmaceutical compositions comprising active vitamin d compounds
IL159725A0 (en) Pharmaceutical compositions containing benzimidazole derivatives
IL157741A0 (en) Pharmaceutical compositions containing an antihyperplastic active agent
HK1072200A1 (en) Pro-micelle pharmaceutical compositions
EP1631239A4 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING ACTIVE COMPOUNDS OF VITAMIN D
GB0319041D0 (en) Pharmaceutical Formulations
GB0111597D0 (en) Pharmaceutical compositions
AU2002341205A1 (en) Pharmaceutical compositions comprising cyclosporin
HK1070840A1 (en) Pharmaceutical compositions based on azetidine derivatives
IL158898A0 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING APOMORPHINE, 6aR-(-)-N-PROPYL-NORAPOMORPHINE AND DERIVATIVES THEREOF
IL156988A0 (en) Pharmaceutical compositions containing epothilone derivatives
IL157128A0 (en) Pharmaceutical compositions containing epothilone derivatives
HUP0400850A3 (en) Oral pharmaceutical compositions
GB0120701D0 (en) Pharmaceutical formulations
GB0103638D0 (en) Pharmaceutical formulations
GB2380129B (en) Pharmaceutical formulations
HK1068277A1 (en) Pharmaceutical compositions comprising chelidonineor derivatives thereof
GB0105560D0 (en) Pharmaceutical formulations
EP1480649A4 (en) STABLE PHARMACEUTICAL COMPOSITIONS
IL172304A0 (en) Pharmaceutical compositions comprising active vitamin d compounds
IL159614A0 (en) Benzofuran derivatives and pharmaceutical compositions containing the same
HUP0302531A3 (en) Pharmaceutical compositions containing citalopram
IL157849A0 (en) Pharmaceutical compositions containing (+) cannabidiol and derivatives thereof and some such novel derivatives
IL157356A0 (en) Pharmaceutical compositions containing a taxane derivative at a low dosage